Terms: = Liver cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Treatment
60 results:
1. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring fgfr2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
Parisi A; Delaunay B; Pinterpe G; Hollebecque A; Blanc JF; Bouattour M; Assenat E; Ben Abdelghani M; Sarabi M; Niger M; Vivaldi C; Mandalà M; Palloni A; Bensi M; Garattini SK; Tougeron D; Combe P; Salati M; Rimini M; Cella CA; Tucci M; Diana A; Mori E; Longarini R; Artru P; Roth G; Evesque L; Vienne A; Turpin A; Hiret S; Bourgeois V; Herve C; Paulon R; Stacoffe M; Malka D; Neuzillet C; Edeline J; Lievre A; Guimbaud R; Chapda MCP; Rimassa L; Giampieri R; Valle J; Berardi R; Fares N
Eur J Cancer; 2024 Mar; 200():113587. PubMed ID: 38340384
[TBL] [Abstract] [Full Text] [Related]
2. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
[TBL] [Abstract] [Full Text] [Related]
3. PTBP1 promotes the progression of hepatocellular carcinoma by enhancing the oncogenic splicing switch of fgfr2.
Yu-Ying C; Qian Z; Meng-Hui G; Lan F; Peng-Bo C; Gang-Qiao Z
Yi Chuan; 2024 Jan; 46(1):46-62. PubMed ID: 38230456
[TBL] [Abstract] [Full Text] [Related]
4. Pemigatinib: A Review in Advanced Cholangiocarcinoma.
Frampton JE
Target Oncol; 2024 Jan; 19(1):107-114. PubMed ID: 38206555
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Profile of Intrahepatic Cholangiocarcinoma.
Andraus W; Tustumi F; de Meira Junior JD; Pinheiro RSN; Waisberg DR; Lopes LD; Arantes RM; Rocha Santos V; de Martino RB; Carneiro D'Albuquerque LA
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203635
[TBL] [Abstract] [Full Text] [Related]
6. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
[TBL] [Abstract] [Full Text] [Related]
7. New Options for Systemic Therapies in Intrahepatic Cholangiocarcinoma (iCCA).
Becht R; Wasilewicz MP
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374378
[TBL] [Abstract] [Full Text] [Related]
8. Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma.
Zhang Z; Wang G; Du L; Zhao J; Pan L; Zhang G; Wang F; Liu R
Front Immunol; 2023; 14():1124482. PubMed ID: 37292215
[TBL] [Abstract] [Full Text] [Related]
9. Cholangiocarcinoma - novel biological insights and therapeutic strategies.
Ilyas SI; Affo S; Goyal L; Lamarca A; Sapisochin G; Yang JD; Gores GJ
Nat Rev Clin Oncol; 2023 Jul; 20(7):470-486. PubMed ID: 37188899
[TBL] [Abstract] [Full Text] [Related]
10. A phase 1b study of the allosteric extracellular fgfr2 inhibitor alofanib in patients with pretreated advanced gastric cancer.
Tsimafeyeu I; Statsenko G; Vladimirova L; Besova N; Artamonova E; Raskin G; Rykov I; Mochalova A; Utyashev I; Gorbacheva S; Kazey V; Gavrilova E; Dragun N; Moiseyenko V; Tjulandin S
Invest New Drugs; 2023 Apr; 41(2):324-332. PubMed ID: 36907947
[TBL] [Abstract] [Full Text] [Related]
11. Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary cancer and Beyond.
Uson Junior PLS; Borad MJ
Semin Liver Dis; 2023 May; 43(2):218-225. PubMed ID: 36882151
[TBL] [Abstract] [Full Text] [Related]
12. Immunology and immunotherapy of cholangiocarcinoma.
Greten TF; Schwabe R; Bardeesy N; Ma L; Goyal L; Kelley RK; Wang XW
Nat Rev Gastroenterol Hepatol; 2023 Jun; 20(6):349-365. PubMed ID: 36697706
[TBL] [Abstract] [Full Text] [Related]
13. Acteoside (Verbascoside): A Prospective Therapeutic Alternative against Hepatocellular Carcinoma by Inhibiting the Expression of AXL, FGFR, BRAF, TIE2 and RAF1 Targets.
Kityania S; Nath R; Nath D; Patra JK; Talukdar AD
Comb Chem High Throughput Screen; 2023; 26(10):1907-1919. PubMed ID: 36321230
[TBL] [Abstract] [Full Text] [Related]
14. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying fgfr2 fusions or rearrangements: A phase II study.
Shi GM; Huang XY; Wen TF; Song TQ; Kuang M; Mou HB; Bao LQ; Zhao HT; Zhao H; Feng XL; Zhang BX; Peng T; Zhang YB; Li XC; Yu HS; Cao Y; Liu LX; Zhang T; Wang WL; Ran JH; Liu YB; Gong W; Chen MX; Cao L; Luo Y; Wang Y; Zhou H; Yang GH; Fan J; Zhou J
Cancer Med; 2023 Feb; 12(4):4137-4146. PubMed ID: 36127767
[TBL] [Abstract] [Full Text] [Related]
15. Precision oncology for intrahepatic cholangiocarcinoma in clinical practice.
Tomczak A; Springfeld C; Dill MT; Chang DH; Kazdal D; Wagner U; Mehrabi A; Brockschmidt A; Luedde T; Naumann P; Stenzinger A; Schirmacher P; Longerich T
Br J Cancer; 2022 Nov; 127(9):1701-1708. PubMed ID: 35986087
[TBL] [Abstract] [Full Text] [Related]
16. Novel insights into molecular and immune subtypes of biliary tract cancers.
Bramel ER; Sia D
Adv Cancer Res; 2022; 156():167-199. PubMed ID: 35961699
[TBL] [Abstract] [Full Text] [Related]
17. Gastric carcinosarcoma with fgfr2 amplification under long-term control with pazopanib: a case report and literature review.
Hayashi H; Makiyama A; Okumura N; Yasufuku I; Saigo C; Takeuchi T; Miyazaki T; Tanaka Y; Matsuhashi N; Murase K; Takahashi T; Futamura M; Yoshida K
BMC Gastroenterol; 2022 Jul; 22(1):360. PubMed ID: 35902814
[TBL] [Abstract] [Full Text] [Related]
18. Proteogenomic characterization of cholangiocarcinoma.
Deng M; Ran P; Chen L; Wang Y; Yu Z; Cai K; Feng J; Qin Z; Yin Y; Tan S; Liu Y; Xu C; Shi G; Ji Y; Zhao JY; Zhou J; Fan J; Hou Y; Ding C
Hepatology; 2023 Feb; 77(2):411-429. PubMed ID: 35716043
[TBL] [Abstract] [Full Text] [Related]
19. Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring
Beri N
Future Oncol; 2022 Apr; 18(11):1391-1402. PubMed ID: 35081733
[TBL] [Abstract] [Full Text] [Related]
20. How I treat biliary tract cancer.
Lamarca A; Edeline J; Goyal L
ESMO Open; 2022 Feb; 7(1):100378. PubMed ID: 35032765
[TBL] [Abstract] [Full Text] [Related]
[Next]
